Saladax Biomedical Appoints Edward L. Erickson as President and CEO

New CEO to lead Company in commercializing personalized medicine products

BETHLEHEM, Pa.--(BUSINESS WIRE)-- Saladax Biomedical, Inc., which is developing and commercializing innovative diagnostic products for personalized medicine, announced today that the Board of Directors elected Edward L. Erickson as the Company’s President and Chief Executive Officer, effective January 3, 2011. Erickson has over 25 years of executive level experience in diagnostics, therapeutics, and life science research products having served as president, CEO or a director of over a dozen companies in these industries.

“Ed Erickson brings substantial range and depth of managerial experience that is immediately and directly relevant to the many opportunities before Saladax. In filling this position the Board sought an individual with experience in overseeing development and commercialization of both diagnostic and therapeutic products across several fields of medicine,” commented Kevin Harter, Executive Chairman of Saladax.

“In order to deliver high-quality healthcare in a cost-effective manner to growing patient populations worldwide, physicians need tools that guide them in using well-established and new drugs better,” said Mr. Erickson. “Saladax’s proprietary diagnostic products are designed to help meet this objective by providing patient-specific information to assist physicians in achieving optimal dosing of drugs in cancer and other fields of medicine. I am honored to join a Company that is pursuing a practical and focused approach to realizing the promise of personalized medicine.”

About Edward L. Erickson

Prior to joining Saladax, Mr. Erickson served as President and CEO of BioNanomatrix, Inc., a privately held genomics company developing and commercializing proprietary DNA analysis systems. Previously, he was the Chairman, President and CEO of Cellatope Corporation, a private company developing diagnostic products in the field of autoimmune diseases. Prior to that, he served in top leadership roles, including president, CEO and/or chairman, of three venture-capital backed medical products companies, Immunicon, DepoTech and Cholestech, which successfully completed initial public offerings under his leadership. Earlier in his career, he held senior executive positions at The Ares-Serono Group and Amersham International. Mr. Erickson is currently a director of BioNanomatrix, Metabolon, and MDxHealth. He holds an MBA from the Harvard Graduate School of Business Administration and B.S. and M.S. degrees from the Illinois Institute of Technology. He did military service as an officer in the U.S. Navy’s nuclear submarine force.

About Saladax Biomedical, Inc.

Saladax Biomedical develops and commercializes novel diagnostic products to achieve the promise of personalized medicine today. The Company's MYCARE™ assays are designed to assist physicians in improving patient outcomes, both in terms of better response to drug therapies and enhanced quality of life through reduced side effects. Saladax, because no two patients are alike.

For more information about Saladax, visit www.saladax.com or view our video at http://www.saladax.com/saladaxvideo. For more information on becoming a companion diagnostic partner, visit http://www.saladax.com/cdx.



CONTACT:

Saladax Biomedical, Inc.
Adrienne Choma, 201-240-4072
[email protected]

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Pharmaceutical  Research  Science  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.

Johns Hopkins researchers developed a biodegradable polymer to transport large therapies into cells—including genes and even CRISPR.

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.